Private investing through venture capital vehicles is an important driver of the US economy and the source of much innovation. The start to 2022 for the industry is mixed because while fundraising, and investing in firms, appears strong, many recent exits don’t look so good, which may clog up the back end of the cycle. About 200 financings of $100 million or more were announced in the first quarter, but deal size and valuation for late-stage companies declined, likely reflecting the complete evaporation of IPOs and a decline in M & A activity. Investors begin to worry about their exits in late-stage firms. Fundraising appeared strong, with $70B in new fund commitments announced, but much of this reflects activity that actually occurred last year, with closings just now being finalized. Fundraising is likely to slow as exits slow. (NVCA Report)
✅ Subscribe via Email
About this Blog
The Healthy Skeptic is a website about the health care system, and is written by Kevin Roche, who has many years of experience working in the health industry. Mr. Roche is available to assist health care companies through consulting arrangements through Roche Consulting, LLC and may be reached at [email protected].
Healthy Skeptic Podcast
This is an outstanding report on total global drug spending and trends, with projections out to 2025. It helps you understand this important area of health care, which does much...
June 1, 2021
MedPAC 2019 Report to Congress
June 18, 2019
In an attempt to swiftly revive two floundering health care companies, a PE firm has announced the merger and recapitalization of Revive Health and SwiftMD. You know they are...
January 30, 2023
Investors have not yet learned their lesson, as Pearl Health gathers a new round of $75 million in capital for its business of supporting physicians who want to participate in...
January 30, 2023
Now here is a tale from the glory days of epidemic investing, as the Feds pumped trillions into the economy and a lot of it went to investing, some to...
January 10, 2023
Access ACO Care Management Chronic Disease Comparative Effectiveness Consumer Directed Health Consumers Devices Disease Management Drugs EHRs Elder Care End-of-Life Care FDA Financings Genomics Government Health Care Costs Health Care Quality Health Care Reform Health Insurance Health Insurance Exchange HIT HomeCare Hospital Hospital Readmissions Legislation M&A Malpractice Meaningful Use Medicaid Medical Care Medicare Medicare Advantage Mobile Pay For Performance Pharmaceutical Physicians Providers Regulation Repealing Reform Telehealth Telemedicine Wellness and Prevention Workplace